palmitoylethanolamide PEA
Selected indexed studies
- Palmitoylethanolamide: A Natural Compound for Health Management. (Int J Mol Sci, 2021) [PMID:34069940]
- Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis. (Nutrients, 2024) [PMID:38892586]
- Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. (Brain Behav Immun, 2022) [PMID:35176443]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Palmitoylethanolamide: A Natural Compound for Health Management. (2021) pubmed
- Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis. (2024) pubmed
- Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. (2022) pubmed
- Role of palmitoylethanolamide (PEA) in depression: Translational evidence: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. (2019) pubmed
- Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. (2025) pubmed
- Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. (2023) pubmed
- Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation. (2021) pubmed
- Palmitoylethanolamide (PEA) for Prevention of Gastroesophageal Inflammation: Insights from In Vitro Models. (2024) pubmed
- Palmitoylethanolamide (PEA) Induces an Increase in Spleen Regulatory T Cells, Reduces CD8 (+) Cells and TNF-α Levels in Target Organs, and Protects Mice From Graft-Versus-Host Disease-Related Mortality Through PPAR Activation Without Compromising the Graft-Versus-Tumour Response. (2025) pubmed
- Lipid mediator palmitoylethanolamide (PEA) inhibits pathogenic T cell differentiation in vitro and in vivo. (2025) pubmed